Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from January 2021.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from January 2021.
5. A Drug Indication Is Pulled From the Market: Now What?
Drug approvals are seemingly happening faster than ever before, with many therapies being granted accelerated approvals based on promising interim results from clinical trials. But what happens when the data in later confirmatory trials is not as good, and treatments may be pulled from the market? Learn more in this piece.
4. Secondline Maintenance PARP Inhibition in Ovarian Cancer: Pros and Cons
While PARP inhibitors in the second-line maintenance setting have allowed some patients with recurrent ovarian cancer to derive prolonged progression-free survival, while being spared chemotherapy-related toxicities, choosing between the 3 approved PARP inhibitors remains a significant challenge, as this piece examines.
3. Managers Can Promote or Improve Nurse Loneliness
Even though nurses may be around people all day, they may still feel lonely, which could lead to job dissatisfaction, compromised patient care, and a high turnover rate among nurses, according to recent research published in the Journal of Nursing Management.
2. Step Count May Boost QOL in Patients Receiving SM-88
Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer, according to trial results presented during the 2021 Gastrointestinal Cancers Symposium.
1. Precision Medicine: Where We've Been, Where We're Going
Targeted therapy and immunotherapy have drastically shifted the cancer landscape in recent years, but there is still more to accomplish in the way of precision medicine, according to the American Cancer Society’s “Blueprint for cancer research: critical gaps and opportunities.”
Thanks for reading!
Maintained QOL, Neurological Function Support T-DXd Safety and Efficacy in HER2+ mBC
December 20th 2024In line with its safety and efficacy profile, T-DXd preserved quality of life and neurological function in patients with HER2-positive metastatic breast cancer, irrespective of brain metastases.